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OBJECTIVES: Patient registries are important tools for health care research. The 
goal of this project, sponsored by the Agency for Healthcare Research and 
Quality (AHRQ), is to design and implement the Registry of Patient Registries 
(RoPR), the first searchable, public database designed specifically to provide 
information about registries. The RoPR is integrated with ClinicalTrials.gov, 
supports research collaboration, reduces redundancy, and improves 
transparency in observational clinical research. METHODS: The RoPR consists of 
a registration system and a public search Web site. The registration system 
collects over forty data elements which define a registry profile. The search site 
serves as a central listing of registries and includes options to filter for relevant 
profiles. RoPR registration is integrated with ClinicalTrials.gov: users registering 
a study on ClinicalTrials.gov who designate it as a patient registry are presented 
with a pop-up window displaying the RoPR registration system. Users complete 
and submit the requested data elements, creating a registry profile in the RoPR 
that is linked to the ClinicalTrials.gov listing through a unique identifier, the NCT 
ID. RESULTS: The RoPR was launched on December 1, 2012. As of January 11, 
2013, 54 new patient registries are registered on ClinicalTrials.gov. Twelve of 
these have been fully published in the RoPR, representing 21 different condition 
areas. Most are classified as disease/disorder/condition (67%), drug (33%), and/or 
procedure (33%) registries. Reported registry purposes include effectiveness 
(50%), safety or harm (42%), natural history of disease (42%) and clinical practice 
assessment (33%). A total of 67% of registry sponsors are open to being contacted 
for collaboration, data access, investigator or patient participation, or for 
information requests. CONCLUSIONS: The RoPR is a searchable Web site used by 
registry sponsors to publish information about registries and by members of  
the public to search for information about existing registries. Integration  
with ClinicialTrials.gov presents a user-friendly interface to encourage 
registration.  
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OBJECTIVES: Post-marketing requirements (PMRs) include studies and clinical 
trials that sponsors are requiredto conduct under one or more statutes or 
regulations. The objective of this research is to identify which therapeutic areas, 
and within these areas, which therapeutic indications have been subjected to the 
highest number of PMRs from the Food and Drug Administration (FDA, USA) and 
the European Medicines Agency (EMA, EU). METHODS: The Post-Marketing 
Requirements Database was used to explore requirements for post-approval 
studies published on the websites of the FDA and the EMA since 2005. The 
search was performed on January 2, 2013. RESULTS: The therapeutic area for 
which the EMA required the highest number of studies was “factors influencing 
health status and contact with health services” (n=36) for the indication 
“prophylaxis of influenza in a pandemic situation” (n=36). Within this indication, 
ten different products were concerned with Pandemrix and Cepalvan being the 
products with the highest number of studies requested (n=6 for each product). In 
comparison, the FDA had requested only 27 studies for the same therapeutic 
area, and neither Pandemrix nor Cepalvan were approved in the USA. The area 
for which the FDA requested the highest number of studies was “endocrine, 
nutritional and metabolic diseases” (n=80), and within this area, the more 
populated indication was “diabetes mellitus”(n=41). Within this indication, 
Onglyza, Byetta and Victoza were the products with the highest number of 
studies requested (n=4, 5, and 6 respectively). In comparison, the EMA had 
requested only 14 studies for the same area. Onglyza, Byetta and Victoza were 
approved in Europe but not subjected to PMRs. CONCLUSIONS: This brief review 
showed discrepancies in PMRs between the FDA and the EMA. More research is 
needed to explain these differences.  
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OBJECTIVES: Patient registries are important tools for health care research, but 
variations in definitions of outcome measures and their data elements make it 
difficult to compare or link data from different registries. Standardizing outcome 
measures would help identify registries capturing similar information and 
promote collaboration, reduce redundancy, and improve efficiencies of new 
registries using standardized data elements. The goal of this project, sponsored 
by the Agency for Healthcare Research and Quality (AHRQ), is to develop a 
prototype of an Outcome Measures Framework (OMF) for use within the Registry 
of Patient Registries (RoPR) to collate and characterize the outcome measures 
currently used in patient registries. The long-term objective of the OMF is to 
support efforts to standardize outcome measures. METHODS: Stakeholders from 
a broad range of organizations (e.g., clinicians, registry sponsors, researchers, 
government agencies) were identified and invited to participate in a series of 
meetings to gather and refine the design requirements for the OMF. 
Requirements were also refined through user acceptance testing. Over 110 
individuals participated in OMF design activities. RESULTS: Stakeholders 
identified several challenges necessary to address in designing the OMF. They 
want a framework that 1) distinguishes between outcome measures collected on 
a patient level and those collected or calculated on a population level; 2) 
describes the frequency or timeframe in which a particular outcome measure is 
collected; 3) identifies outcome measures that are clinically equivalent to each 
other and clearly displays this information; and 4) minimizes user burden, since 
participation in the RoPR is currently voluntary. CONCLUSIONS: By using a 
design process that solicited the opinions of a wide variety of stakeholders, 
several challenges were identified. These challenges were addressed in the 
design of the OMF prototype, and will require further clarification if the OMF is 
developed and implemented into a system such as the RoPR.  
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OBJECTIVES: Multimorbidity has a negative impact on health-related quality of 
life (HRQL). Previous studies included only a limited number of frequent 
conditions and their combinations. The aim of this study was to analyse the 
relative impact of a large number of chronic conditions on overall HRQL in 
multimorbid patients. METHODS: This analysis is based on the MultiCare Cohort 
study, a multicenter, prospective cohort study of 3189 multimorbid primary care 
patients aged 65 to 85. The impact of 45 conditions on HRQL was analysed. The 
severity of the conditions was rated between 0 (insignificant) and 4 (very severe). 
The EQ-5D, a questionnaire consisting of 5 items (dimensions) and a visual-
analogue-scale (EQ VAS) was employed to measure HRQL. Data were analyzed 
using multiple ordinary least squares regression and multiple logistic regression. 
RESULTS: Multimorbidity measured by a weighted count score was significantly 
associated with lower overall HRQL (EQ VAS). Parkinson´s disease had the most 
pronounced negative effect on overall HRQL (EQ VAS), followed by rheuma, 
depression, obesity and cardiac insufficiency. With regard to the individual EQ-
5D dimensions, depression and obesity affected all five dimensions of the EQ-5D 
negatively except for the dimension anxiety/depression. Obesity had a positive 
effect on this dimension. Cardiac insufficiency was associated with three 
dimensions. The dimensions `self-care´ and `usual activities´ were most strongly 
affected by Parkinson´s disease. CONCLUSIONS: The overall HRQL of 
multimorbid patients decreases with an increasing count and severity of 
conditions. Parkinson´s disease, depression and obesity have the strongest 
impact on health-related quality of life.  
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OBJECTIVES: Self-rated health (SRH) has been shown to be a good predictor of 
mortality. However, there are mixed findings of the association between 
mortality and SRH measures with different reference points (i.e., with respect to 
either global or peer age group). This study assessed whether SRH measures with 
different reference frames influence the association of the SRH and mortality in 
old population. METHODS: We analyzed data from 2000-2005 Medical 
Expenditure Panel Survey (MEPS) respondents in Panel 5-7, aged 60 or over, 
linked to the National Death Index (NDI) through 2006. To test whether the SRH 
measures with different reference points were comparable measures to predict 
mortality, two SRH measures (global and age-comparative SRHs) were applied 
separately and concurrently. Cox proportional hazards model was conducted, 
adjusted for demographic and social characteristics. RESULTS: A total of 4787 
respondents were included in the analysis. More respondents were likely to 
assess their health as excellent or very good on the age-comparative SRH 
measure than on the global SRH measure (excellent, 14.7% vs. 7.6%; very good, 
28.6% vs. 25.8%, respectively). In the independent models, ‘poor’ SRH ratings 
were the strongest predictor of mortality. Poor global SRH ratings increased 
mortality risk by 5.06 times and poor age-comparative SRH rating increased 
mortality risk by 5.02 times compared to their respective excellent ratings. When 
two measures were concurrently analyzed in the relation to mortality risk, both 
measures significantly predicted mortality and poor global SRH ratings were the 
strongest predictor of mortality (Hazard ratio = 2.75; 95% CI = [1.694, 4.469]). 
CONCLUSIONS: In this study, both global and age-comparative SRH measures 
were associated with increased risk of mortality. However, we also found that 
the global SRH measure tended to have more predictive power than the age-
comparative measure. Our findings imply that the different reference points may 
affect the association between SRH measures and mortality.  
